BC Innovations | Aug 16, 2018
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse and rat studies suggest inhibiting PANX1 or its activator P2RX7 in spinal microglia, or an antibody-drug conjugate (ADC) targeting the microglia, could help treat joint pain. In spinal cord samples from a...
BC Innovations | Jul 10, 2018
Distillery Therapeutics

Neurology

INDICATION: Pain Cell culture and mouse studies identified a TRPM8 antagonist that could help treat pain. Chemical synthesis of dibenzyl tryptamine analogs and HEK cell-based ion channel assays yielded a compound that inhibited TRPM8 with...
BioCentury | Apr 27, 2018
Emerging Company Profile

Cinclus’ acid inhibition

Cinclus Pharma AG is developing a fast-acting potassium-competitive acid blocker designed to last longer than proton pump inhibitors and marketed P-CABs to treat severe erosive gastrointestinal reflux disease. PPIs such as Nexium esomeprazole and Prilosec...
BC Week In Review | Jan 5, 2018
Company News

RaQualia, Maruho in deal for sodium channel blocker

RaQualia Pharma Inc. (JASDAQ:4579) granted Maruho Co. Ltd. (Osaka, Japan) exclusive, worldwide rights to develop and commercialize an undisclosed selective sodium channel blocker. RaQualia will receive an undisclosed upfront payment and is eligible for development...
BC Innovations | Aug 4, 2016
Finance

2Q16 Public-Private Partnership Roundup

A new consortia revival helped boost public-private partnerships (PPPs) in 2Q16 to the highest total in two years. Newly announced preclinically focused deals jumped 30% over the relatively sluggish first quarter, from 56 PPPs to...
BC Week In Review | Apr 4, 2016
Company News

Asahi Kasei Pharma, RaQualia deal

Asahi and RaQualia partnered to discover pain compounds targeting an undisclosed ion channel. The partners will use RaQualia’s drug development technology. RaQualia will receive an undisclosed research collaboration payment and will be eligible for undisclosed...
BC Week In Review | Jan 11, 2016
Company News

RaQualia, Sihuan deal

RaQualia and Sihuan’s Shandong XuanZhu Pharma Co. Ltd. subsidiary partnered under a three-year deal to discover and develop analgesic compounds. The partners will use multiple lead identification approaches, including high throughput screening, to identify compounds...
BC Week In Review | Dec 14, 2015
Company News

CJ, Shandong Luoxin Pharmaceutical Group deal

CJ Group’s CJ HealthCare Corp. affiliate granted Shandong exclusive rights to develop and commercialize CJ-12420 in China. CJ will receive an upfront payment and is eligible for clinical, regulatory and performance-based milestones plus double-digit royalties....
BC Extra | Nov 20, 2015
Company News

Ipsen, Interprotein in endocrine disease deal

Ipsen Group (Euronext:IPN; Pink:IPSEY) and Interprotein Corp. (Osaka, Japan) partnered to develop therapeutic peptides to treat endocrine diseases including Cushing's disease. Ipsen will have an exclusive option to license candidates developed during the partnership. Interprotein...
BC Week In Review | Aug 3, 2015
Company News

RaQualia, Durata Therapeutics deal

RaQualia elected to regain Japanese rights to dalbavancin from Allergan plc (NYSE:AGN, Dublin, Ireland). In December 2010, RaQualia granted Durata Japanese rights to the second-generation glycopeptide antibiotic. Allergan acquired Durata in November. The drug is...
Items per page:
1 - 10 of 81
BC Innovations | Aug 16, 2018
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse and rat studies suggest inhibiting PANX1 or its activator P2RX7 in spinal microglia, or an antibody-drug conjugate (ADC) targeting the microglia, could help treat joint pain. In spinal cord samples from a...
BC Innovations | Jul 10, 2018
Distillery Therapeutics

Neurology

INDICATION: Pain Cell culture and mouse studies identified a TRPM8 antagonist that could help treat pain. Chemical synthesis of dibenzyl tryptamine analogs and HEK cell-based ion channel assays yielded a compound that inhibited TRPM8 with...
BioCentury | Apr 27, 2018
Emerging Company Profile

Cinclus’ acid inhibition

Cinclus Pharma AG is developing a fast-acting potassium-competitive acid blocker designed to last longer than proton pump inhibitors and marketed P-CABs to treat severe erosive gastrointestinal reflux disease. PPIs such as Nexium esomeprazole and Prilosec...
BC Week In Review | Jan 5, 2018
Company News

RaQualia, Maruho in deal for sodium channel blocker

RaQualia Pharma Inc. (JASDAQ:4579) granted Maruho Co. Ltd. (Osaka, Japan) exclusive, worldwide rights to develop and commercialize an undisclosed selective sodium channel blocker. RaQualia will receive an undisclosed upfront payment and is eligible for development...
BC Innovations | Aug 4, 2016
Finance

2Q16 Public-Private Partnership Roundup

A new consortia revival helped boost public-private partnerships (PPPs) in 2Q16 to the highest total in two years. Newly announced preclinically focused deals jumped 30% over the relatively sluggish first quarter, from 56 PPPs to...
BC Week In Review | Apr 4, 2016
Company News

Asahi Kasei Pharma, RaQualia deal

Asahi and RaQualia partnered to discover pain compounds targeting an undisclosed ion channel. The partners will use RaQualia’s drug development technology. RaQualia will receive an undisclosed research collaboration payment and will be eligible for undisclosed...
BC Week In Review | Jan 11, 2016
Company News

RaQualia, Sihuan deal

RaQualia and Sihuan’s Shandong XuanZhu Pharma Co. Ltd. subsidiary partnered under a three-year deal to discover and develop analgesic compounds. The partners will use multiple lead identification approaches, including high throughput screening, to identify compounds...
BC Week In Review | Dec 14, 2015
Company News

CJ, Shandong Luoxin Pharmaceutical Group deal

CJ Group’s CJ HealthCare Corp. affiliate granted Shandong exclusive rights to develop and commercialize CJ-12420 in China. CJ will receive an upfront payment and is eligible for clinical, regulatory and performance-based milestones plus double-digit royalties....
BC Extra | Nov 20, 2015
Company News

Ipsen, Interprotein in endocrine disease deal

Ipsen Group (Euronext:IPN; Pink:IPSEY) and Interprotein Corp. (Osaka, Japan) partnered to develop therapeutic peptides to treat endocrine diseases including Cushing's disease. Ipsen will have an exclusive option to license candidates developed during the partnership. Interprotein...
BC Week In Review | Aug 3, 2015
Company News

RaQualia, Durata Therapeutics deal

RaQualia elected to regain Japanese rights to dalbavancin from Allergan plc (NYSE:AGN, Dublin, Ireland). In December 2010, RaQualia granted Durata Japanese rights to the second-generation glycopeptide antibiotic. Allergan acquired Durata in November. The drug is...
Items per page:
1 - 10 of 81